# US 11,999,776 B2 · IGFR-like 2 receptor and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,776 B2
- Document ID: US11999776B2
- Status: Granted
- Kind: B2
- Application number: 17/412,066
- Filed: 2021-08-25
- Published: 2022-02-17
- Granted: 2024-06-04
- Earliest claimed: 2017-01-30
- Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
- Applicants: Helmholtz Zentrum München—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)
- Inventors: Heiko Lickert; Ünal Coskun; Sarah Homberg
- Web page: https://patentgrep.com/patent/US11999776B2

## CPC

- C07K 14/71: for growth factors; for growth regulators
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- G01N 33/5041: {involving analysis of members of signalling pathways}
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a novel IGFR-like receptor 2 and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of cancer or diabetes.

## Claims

### Claim 1

An in vitro screening method for antagonists of an IGFR-like receptor 2, said method comprising steps of:
(a) providing a stable cell line expressing said IGFR-like receptor 2;
(b) contacting said cell line with a candidate antagonist of the IGFR-like receptor 2; and
(c) measuring IGFR-like receptor 2 downstream signaling events comprising (i) InsR phosphorylation, (ii) AKT phosphorylation, or both (i) and (ii),
wherein an antagonist of the IGFR-like receptor 2 is identified if it causes an increase in (i) InsR phosphorylation, (ii) AKT phosphorylation, or both (i) and (ii),
wherein said IGFR-like receptor 2 comprises a sequence corresponding to sequence SEQ ID NO: 2.

### Claim 2 (depends on 1)

The in vitro method of claim 1, wherein said candidate antagonist is selected from an antibody, a siRNA, a nucleic acid, an aptamer, a peptide, a protein, or a small molecule organic compound.

### Claim 3 (depends on 2)

The in vitro method of claim 2, wherein said antibody is a monoclonal or polyclonal antibody.

### Claim 4 (depends on 1)

The in vitro method of claim 1, wherein said cell line is Min6 cells or PDX1+/NKX6.1+iPSC cells.

### Claim 5 (depends on 1)

The in vitro method of claim 1, wherein the measuring of said (i) InsR phosphorylation, (ii) AKT phosphorylation, or both (i) and (ii), of step (c) is compared to (i) InsR phosphorylation, (ii) AKT phosphorylation, or both (i) and (ii), measured in a control cell line that was not contacted with said candidate antagonist.